AMENDMENT TO SERIES C WARRANTS TO PURCHASE COMMON STOCK
EXHIBIT 10.3
AMENDMENT TO SERIES C WARRANTS TO PURCHASE COMMON STOCK
This Amendment to Series C Warrants to Purchase Common Stock (the “Amendment”) by and between Arch Therapeutics, Inc., a Nevada corporation (the “Company”), and Cranshire Capital Master Fund, Ltd. (“Cranshire”) is made as of March 13, 2015 (the “Effective Date”).
RECITALS
WHEREAS, on January 30, 2014, the Company entered into that certain Securities Purchase Agreement (the “Securities Purchase Agreement”) with the investors named on the Schedule of Buyers attached thereto (collectively, the “Holders”) pursuant to which, among other things, the Company issued to the Holders shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and the Series C Warrants (as defined in the Securities Purchase Agreement, the “Series C Warrants”);
WHEREAS, Section 9 of the Series C Warrants provides that the provisions of the Series C Warrants may be amended only with the written consent of the Company and the Significant Buyers (as defined in the Securities Purchase Agreement);
WHEREAS, Cranshire is the only Significant Buyer; and
WHEREAS, the Company and Cranshire, in its capacity as the only Significant Buyer, now wish to amend the Series C Warrants as of the Effective Date as set forth herein.
NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency which are hereby acknowledged, the Parties hereby agree as follows:
| 1. | Definitions. Capitalized terms not otherwise defined in this Amendment shall have the meaning given to them in the Series C Warrants. |
| 2. | Amendments to Series C Warrants. Section 16(h) to the Series C Warrants is hereby amended as of the Effective Date as follows: |
“(h) “Expiration Date” means 5:00 p.m., New York time, on June 2, 2015.”
| 3. | Representations and Warranties of the Company. The Company represents and warrants to Cranshire that, after giving effect to the Amendment, the Warrant Shares shall remain eligible for resale under the Company’s resale registration statement on Form S-1 (File Number 333-194745) that became effective July 2, 2014. |
| 4. | Miscellaneous. To the extent
that there are any inconsistencies between the terms of any Series C Warrant and the
terms of this Amendment, the terms of this Amendment shall prevail in effect. This Amendment
may be executed by the Parties in counterparts and may be executed and delivered by facsimile
or other means of electronic communication and all such counterparts, taken together,
shall constitute one and the same agreement. A signed copy of this Amendment delivered
by facsimile, e-mail or other means of electronic transmission shall be deemed to have
the same legal effect as delivery of an original signed copy of this Amendment. It is
expressly understood and agreed that (i) this Amendment shall be a Transaction Document
and (ii) the Transaction Documents are hereby amended to give full force and effect to
the transactions contemplated by this Amendment. Except as otherwise expressly provided
herein, (1) the Series C Warrants and each other Transaction Document is, and shall continue
to be, in full force and effect and is hereby ratified and confirmed in all respects,
except that on and after the Effective Date (A) all references in the Series C Warrants
to “this Warrant,” “hereto,” “hereof,” “hereunder”
or words of like import referring to the Series C Warrants shall mean the Series C Warrants
as amended by this Amendment, (B) all references in the other Transaction Documents to
the “Warrants,” “thereto,” “thereof,” “thereunder”
or words of like import referring to the Series C Warrants shall mean the Series C Warrants
as amended by this Amendment and (C) all references in Transaction Documents to the “Transaction
Documents,” “thereto,” “thereof,” “thereunder”
or words of like import referring to the Transaction Documents shall mean the Transaction
Documents as amended by this Amendment and (2) the execution, delivery and effectiveness
of this Amendment shall not operate as an amendment or waiver of any right, power, benefit
or remedy of any Holder under any Transaction Document, nor constitute an amendment of
any provision of any Transaction Document and all of them shall continue in full force
and effect, as amended or modified by this Amendment. |
[signature page follows]
| -2- |
IN WITNESS WHEREOF, Cranshire and the Company have caused their respective signature page to this Amendment to be duly executed as of the date first written above.
| ARCH THERAPEUTICS, INC. | |||
| By: | |||
| Name: Xxxxxxxx X. Xxxxxx, M.D | |||
| Title: President, Chief Executive Officer | |||
| SIGNIFICANT BUYER: | |||
| CRANSHIRE CAPITAL MASTER FUND, LTD. | |||
| By: Cranshire Capital Advisors, LLC | |||
| Its: Investment Manager | |||
| By: Xxxxx Xxxxxxx | |||
| Its: Authorized Signatory | |||
